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Henry I. Bowditch Public Health Council Room, 2nd Floor 
250 Washington Street, Boston MA 
 
 
Docket: Thursday, October 15, 2015 9:00 AM 
 
 
1. ROUTINE ITEMS: 
 
a. Welcome and Opening Remarks  
 
b. Approval of the Minutes (Vote) 
 
 
2. REVIEW OF OCTOBER 1, 2015 MEETING: 
 
a. Feedback from Invited Panelists 
 
 
3. DISCUSSION OF EVALUATION CRITERIA: 
 
a. Heightened Public Health Risk Criteria  
 
i. Drug Groups (Vote) 
 
 
b. Therapeutically Equivalent Substitution Criteria  
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Drug Formulary Commission 
 
Presented below is a summary of the meeting, including time-keeping, attendance and votes cast.  
 
Date of Meeting: Thursday, October 15, 2015 
Beginning Time:  9:04 AM 
Ending Time:   11:52 AM 
Attendance and Summary of Votes:  
 
Board Member Attended Minutes Heightened Public Health 
Risk Criteria: Drug Groups 
Dr. Dan Alford Absent Absent Absent 
Dr. Douglas Brandoff 
Yes Yes 
 
Yes 
Cheryl Campbell Absent Absent Absent 
Ray Campbell III Yes Yes Yes 
Dr. Daniel Carr Yes Not Voting Yes 
Joanne Doyle-Petrongolo 
Yes Yes 
 
Yes 
Stephen Feldman 
Yes Yes Yes 
Dr. Kenneth Freedman Yes Not Voting Yes 
Dr. Paul Jeffrey Yes- arrived at 9:27 AM Not Voting Yes 
Virginia Lemay Yes Yes Yes 
Eric Sheehan Yes Not Voting Not Voting 
Cindy Steinberg 
Yes Yes 
 
Yes 
Dr. Jeffrey Supko 
Absent Absent 
 
Absent 
Dr. Theoharis Theoharides 
Absent Absent 
 
Absent 
Tammy Thomas 
Yes Yes 
 
Yes 
Dr. Alexander Walker 
Absent Absent 
 
Absent 
Summary 
11 
Members attended 
 
7 
Approved with votes 
 
10 
Approved with votes 
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1. PROCEEDINGS 
 
A regular meeting of the Drug Formulary Commission (M.G.L. Ch. 17, § 13) was held on Thursday, October 
15, 2015 at the Massachusetts Department of Public Health, 250 Washington Street, Henry I. Bowditch 
Public Health Council Room, 2nd Floor, Boston, Massachusetts 02108.  
 
Members present were:  Department of Public Health Interim Director of the Bureau of Health Care 
Safety and Quality, Eric Sheehan (Chair), Dr. Douglas Brandoff, Dr. Daniel Carr, Mr. Ray Campbell III, Dr. 
Joanne Doyle-Petrongolo, Mr. Stephen Feldman, Dr. Kenneth Freedman, Dr. Paul Jeffrey, Dr. Virginia 
Lemay, Ms. Cindy Steinberg, and Ms. Tammy Thomas.   
 
Absent members were: Dr. Dan Alford, Ms. Cheryl Campbell, Dr. Jeffery Supko, Dr. Theoharis Theoharides, 
and Dr. Alexander Walker. 
 
Also in attendance were the following staff from the Department of Public Health: Suzanne Cray, Director 
of the Office of Health Care Integration at the Bureau of Health Care Safety and Quality; Jonathan Mundy, 
Director of the Office of Prescription Monitoring and Drug Control at the Bureau of Health Care Safety and 
Quality; Lauren Nelson, Director of Policy and Quality Improvement at the Bureau of Health Care Safety 
and Quality; and David Dunn, Associate Executive Director of the Board of Registration in Pharmacy. 
 
Interim Director Sheehan called the meeting to order at 9:04 AM.  He reminded the members that the 
meeting was being recorded. Interim Director Sheehan thanked the Commission members for attending 
the first three meetings and assessed the current status of the Commission.  
 
He began by talking about the last meeting on October 1.  He stated during this meeting, we heard 
extensive feedback from a diverse group of experts related to their experience with drug formularies.  We 
also heard helpful comments on their recommendations as to how the Commission should evaluate 
potential therapeutically equivalent substitutes based on the four factors outlined in Chapter 258.  He 
stated as a reminder, the four factors are: 
 The efficacy of the drug; 
 The effectiveness of its abuse deterrent properties; 
 The accessibility of the drug; and 
 The cost effectiveness. 
 
Interim Director Sheehan stated that at today’s meeting, we will discuss the comments and written 
testimony received from the experts and other stakeholders.  We will consider this feedback as we 
continue development of the evaluation and review criteria that the Commission will use to complete the 
components of its work.   
 
Interim Director Sheehan reviewed the current status of the Commission’s work in the Evaluation and 
Review Process. He stated the Commission’s task is to develop a formulary that consists of three 
components. 
 
Component 1: The Commission will determine which groups of drugs should be designated as having a 
heightened public health risk.  
 
Component 2: The Commission will determine which drugs should be identified as therapeutically 
equivalent substitutes to the drugs that have a heightened public health risk.   
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Component 3: The Commission will complete a crosswalk and develop a formulary of therapeutically 
equivalent substitutes for drugs determined to be having a heightened public health risk. 
 
He added following completion of these components, the Commission will have a draft formulary.  He 
stated we have spent time understanding the process to develop the drug formulary and the timeline for 
achieving our goals.  Our last meeting allowed us to hear outside perspectives as we make process on our 
work plan for developing the formulary.  
 
Considering the work and discussion to date, our next key task is to establish the criteria in which the 
Commission will determine if a drug should be placed on the formulary as having a heightened public 
health risk or as a therapeutically equivalent substitute. He stated our goal for today’s meeting is to make 
significant progress on the creation of the criteria, potentially even voting to finalize aspects of it.  
 
By meeting this goal, we will be in the position to start reviewing the application of the final criteria to 
specific drugs at our November meetings.  This will keep us on target to evaluate specific drugs over the 
winter months and have a draft formulary completed in the winter. 
 
Interim Director Sheehan asked if there were any changes to minutes from the October 1
st
 meeting, after 
which Dr. Doyle-Petrongolo had a comment to add her statement made at the meeting to include the 
formulary as part of the electronic health record.  
 
Interim Director Sheehan then asked if there was a motion to vote to approve the minutes with this 
addition, and Ms. Steinberg motioned to approve the minutes, and Mr. Feldman seconded the motion for 
approval of the minutes. Interim Director Sheehan declared the minutes approved after a unanimous 
vote.  Dr. Jeffery was not present for the discussion or vote of this matter. 
 
2. REVIEW OF OCTOBER 1 MEETING 
 
Interim Director Sheehan reminded Commission members that, the goal of the October 1
st
 meeting was 
to make sure that the Commission has the most relevant, timely and beneficial information available and 
get expert feedback to consider as part of the work to develop the formulary.  He added that we heard 
from 11 experts from diverse fields and received written testimony from 7 individuals, including 4 that 
gave remarks.   
 
He mentioned that all testimony was provided to Commission members in advance so that we could 
review and discuss the major points that were raised. Interim Director Sheehan specifically addressed 
testimony that Commission members heard during the October 1
st
 meeting regarding the need for the 
Commission to use chemical versus therapeutically equivalent drug products as substitutes to drugs that 
have been determined to have a heightened public health risk. Interim Director Sheehan reminded 
Commission members that this topic was discussed at the September 8
th
 meeting and noted that it was 
the Department’s responsibility to review and interpret the statute.  From this review, the intent was for a 
formulary of therapeutic substitutes to be determined.  
 
Next, Interim Director Sheehan introduced David Dunn to facilitate a discussion of the observations from 
the October 1
st
 meeting.   
 
Associate Executive Director Dunn conducted a presentation of the key observations from the meeting.  
He noted that some of the points stressed by testifiers, such prescriber education, and the prior 
authorization process, may fall outside of the scope of the Drug Formulary Commission but is still relevant 
feedback to consider as we take a holistic view of the work before the Commission. 
 
6 
 
Mr. Feldman stated he though the panel meeting was valuable but believes that many testifiers thought 
the formulary was mandatory and not voluntary for prescribers to utilize.  Interim Director Sheehan 
provided clarification that the formulary is just one aspect of the tools available to prescribers but is not 
mandated.  Even after the Commission votes on a draft formulary, it will be a fluid document and will 
change.  It also needs to go through the regulation review and promulgation process, including 
presentation to the Public Health Council.   
 
Ms. Steinberg asked if the formulary was still flexible and not mandatory if it needs to be adopted by 
regulation.  Interim Director Sheehan stated that it was as it was a tool to assist prescribers.  We are not 
here to dictate the patient-prescriber relationship. 
 
Dr. Paul Jeffrey arrived at 9:26 AM. 
 
Associate Executive Director Dunn added that if a practitioner wants to use the substitution 
recommended by the formulary, he would have to prescribe it.  Drug and strength changes must only 
made by the practitioner based on federal law. He clarified that a pharmacist can make a generic 
substitution but not a therapeutic substitution of controlled substances in Schedule II. 
 
Dr. Freedman brought up Mr. Feldman’s previous point, stating that it seemed like some testifiers 
believed it would be mandatory formulary and worried about delay in therapy providing the prescription.  
This should not be an issue if the formulary is voluntary because the pharmacist would not need to seek 
out the prescriber if substituting.  He added as an example that there are 4 different formulations of 
buprenorphine and many managed care companies have a preferred formulation that can cause delay if 
patient not prescribed one of the preferred medications. It needs to be put in an introduction to the 
formulary that it is voluntary.   
 
Dr. Freedman also noted that the testifiers felt that it was important for there to be recommendations of 
safe prescribing.  Even if it is not within the jurisdiction of this Commission, it is an important issue and 
maybe we can share these recommendations with an appropriate body.  Interim Director Sheehan noted 
that it is not within the Commission’s jurisdiction but it is an issue that is being considered by other areas 
within the Department.  He noted that it may be possible to have the Department’s Bureau of Substance 
Abuse Services (BSAS) present on their efforts. 
 
Dr. Brandoff stated he understands that the Commission needs to stay within its authority but we need to 
think about the impact of the formulary and other recommendations even if they are not mandatory. 
 
Dr. Doyle-Petrongolo indicated that there are still prescribers that do not know what the PMP is or are not 
using it to the fullest extent.  Interim Director Sheehan responded that the new MA Online PMP is a top 
initiative that is still in the procurement phase but we will give a full update to the Commission once we 
are able.   
 
Dr. Carr stated we have an action item of needing a clear statement that education is important.  
Governor Baker and Commissioner Bharel are put together a panel of the four deans of Massachusetts’ 
medical schools on this issue.  He also stated that we need to clarify that chemically equivalent can be 
interpreted as therapeutically equivalent as having the same course of action in a chemical class.  He 
believes that the intent of Chapter 258 is referring to therapeutically equivalent substitutes among the 
“same mechanism of action.” 
 
Dr. Feldman stated we should provide an algorithm to guide the use of the formulary. 
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Dr. Lemay wanted to reiterate how important it is for this to be a smooth process and we need to keep 
communication open with insurer partners to ensure access. 
 
3. DISCUSSION OF EVALUATION CRITERIA 
 
Interim Director Sheehan started the next agenda item but stating that it was important that we work to 
finalize the evaluation criteria so we can begin to use it in the evaluation of drug products.  We will revisit 
comments and discussion from previous meetings and the expert feedback received on October 1.  The 
Department has taken all of this feedback and developed draft criteria for your consideration. 
 
Interim Director Sheehan introduced Associate Executive Director Dunn to facilitate conversation on the 
evaluation criteria, starting with the heightened public health risk criteria.  
 
Associate Executive Director Dunn stated at our September 8
th
 meeting, there was discussion and 
momentum to classify all drugs that have already been designated by the DEA as Schedule II and Schedule 
III as having a heightened public health risk. He added the DEA definition of Schedule II includes the drug 
having a high potential for abuse and is considered dangerous. He stated Schedule III drugs are defined as 
having a moderate to low potential for dependence.  
 
From this information and previous conversation on the topic, Associate Executive Director Dunn asked if 
the Drug Formulary Commission wants to place all Schedule II and III drug groups on the formulary as 
having a heightened public health risk.   
 
Interim Director Sheehan thanked you Mr. Dunn for providing this overview. Interim Director Sheehan 
clarified that should the Commission decide to place all of the Schedule II and III groups on the formulary 
as having a heightened public health risk, this decision becomes an inclusionary decision.  He added this 
would mean that all of the drug products in each individual drug group would also be considered a 
heightened public health risk.  Interim Director Sheehan states this would include 333 individual drug 
products in all of the Schedule II groups and 48 individual drug products in all of the Schedule III groups.  
 
Interim Director Sheehan stated should the DFC decide not to place all of the Schedule II and II groups on 
the formulary as having a heightened public health risk, it would require review, analysis and vote on each 
individual drug within each drug group. These actions make this decision an exclusionary decision. With 
this decision, 333 individual drugs products would have to be reviewed in all Schedule II drug groups and 
48 individual drug products would have to be reviewed in all Schedule III drug groups.  
 
He further stated that we will have a review process to determine if drugs are appropriate therapeutically 
equivalent substitutes to include on the formulary but it will be different than determining if a drug has a 
heightened public health risk.  This will be discussed later today.  We have presented this question to the 
Commission based on the conversation among the members at our September 8
th
 meeting, which 
indicated a likelihood of consensus to apply all the Schedule II and III drug groups to the formulary as 
having a heightened public health risk. 
 
Interim Director Sheehan stated we also know that the DEA has already designated these drugs has 
having a public health risk component. He added we raise it today to try to determine if there is a 
consensus to take this action. 
 
Ms. Steinberg stated Massachusetts General Law Chapter 94C includes how drugs are to be classified and 
that scheduling has taken into consideration the risk of abuse.  I think that the legislative intent of Chapter 
258 is for the Commission to identify a subset of these drugs that have a heightened public health risk.   
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Dr. Jeffrey suggested that if there won’t ever be a therapeutically equivalent ADF substitute, then why put 
the drug on the formulary as having a heightened public health risk?  Associate Executive Director Dunn 
stated that as a practical matter, there are some drugs that do not have a ADF today but including the 
drug on the formulary as having a heightened public health risk allows us to move the process forward 
and be ready for future advancements.  
 
Dr. Brandoff asked how the vote on the drugs to include as having a heightened public health risk does 
more than the current scheduling of these drugs?  Associate Executive Director Dunn noted that it allows 
this to be an inclusionary process versus an exclusionary process.  Dr. Brandoff asked how the PMP data 
will be worked in and Mr. Dunn responded that it will be used as part of the draft monograph, which will 
be discussed later. 
 
Mr. Feldman noted that things change so quickly, that everything should be included just to make sure 
that if it becomes an issue later, we will already have it on our radar.  As substitutions become available, 
we will be able to look back at some of these drugs that were included as heightened, but did not have a 
substitute on the formulary. Interim Director Sheehan noted that the DEA already made the 
determination based on criteria and the decision to include all Schedule II and Schedule III drug groups on 
the formulary supports that.  This will be a fluid process and we will be able to revisit the formulary and 
make future determinations. The goal is for this determination to allow us to move on and have a more 
expedient process based on the DEA’s previous decisions.   
 
Dr. Carr noted that the burden of proof is on us to determine if a drug does not have a heightened public 
health risk by definition.  He supports an inclusive process. 
 
Dr. Freedman is in support of including all of the Schedule II and Schedule III drug products but would 
suggest a more pragmatic approach would be to start with Schedule II drugs and complete Schedule III 
drugs later. 
 
Mr. Feldman asked if this work ends and begins with opioids.  Interim Director Sheehan noted that 
Chapter 258 indicates that our work is related to Schedule II and III opioids. 
 
Dr. Brandoff stated that he is clear on what heightened public risk means for the Commission’s purpose 
but that doesn’t mean that a product will be taken off the market.  
 
Interim Director Sheehan stated after hearing all your thoughts, I’d like to ask if there is motion to place 
all Schedule II and III opioids on the formulary as having a heightened public health risk. Dr. Freedman 
made the motion to include all Schedule II and III drug products on the formulary as having a heightened 
public health risk.  This was seconded by Dr. Carr and the vote was unanimous. 
 
Interim Director Sheehan called upon a break at 10:15 am, to resume the meeting at 10:25 am. 
 
Following the break, Interim Director Sheehan indicated that Associate Executive Director Dunn will 
continue the presentation to bring us on to our next topic, establishing the criteria for the determination 
of therapeutically equivalent substitutes. 
 
Associate Executive Director Dunn continued his presentation and went over the review process for 
determining if a drug should be placed on the formulary as being a therapeutically equivalent drug 
product.  He discussed the need to use evidence-based decision making and reviewed literature and data 
elements to consider as part of the criteria to determine if a drug is a therapeutically equivalent 
substitute.   
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Associate Executive Director Dunn introduced the use of a monograph to apply this criteria to the 
evaluation of the drugs.  He indicated that the monograph will be completed for each drug product, 
ensuring consistency and transparency.  The draft monograph was displayed at the meeting and copies 
were provided to the Commission members in their binders.   
 
Dr. Carr asked if we are only looking at different specific formulations?  Associate Executive Director Dunn 
stated that is up to the Commission for discussion.  
 
Mr. Feldman asked how data from the PMP will be part of review and decision making.  Associate 
Executive Director Dunn indicated that PMP data has been requested by the Commission and will be used 
to look at decision-making.  Mr. Feldman asked if the data will show, in the aggregate, what people are 
being prescribed.  Associate Executive Director Dunn said yes.  Mr. Mundy clarified the drugs that are 
reported to the PMP.  Pain management drugs do go into the PMP but not doctor’s orders for addiction 
management.   
 
Mr. Feldman provided feedback on slide 26 and stated that we want to be specific on the data to include 
as we will want to know the efficacy measures and if the ADF has deterred.  He also stated other edits for 
inclusion in the criteria. 
 
Dr. Jeffrey noted that we want to look at popular websites that show people how to circumvent the ADFs.   
 
Dr. Lemay suggested that clinical practice guidelines be included. 
 
Dr. Carr stated that we should revisit the scope of the drug and look at other reviews such as the 
Cochrane Review.  There should also be a phrase included to acknowledge individual variability.   
 
Associate Executive Director Dunn then went into more detail on the draft monograph.   
 
Dr. Freedman asked of all the 381 individual drug products within Schedule II and III, how many would 
meet the criteria for Section 2 of the draft monograph.  Associate Director Dunn did not know.   
 
Interim Director Sheehan sated that we wanted to start the discussion with you around the criteria in the 
monograph.  As way of introduction, we wanted to identify ways to streamline the review process and 
prioritize drugs for your review.   
 
Dr. Carr suggested that we think about this as a sensitivity analysis to provide evidence to make a 
determination.   
 
Mr. Campbell asked if we were to get overdose data, if it can be worked into the threshold in the 
monograph for the criteria of prescriptions written and dosage units dispensed as we don’t want to not 
review drugs that don’t meet this criteria but are widely abused.  Interim Director Sheehan responded 
stating that data requests from the Commission will start being presented in November.   
 
Dr. Brandoff stated that he liked that the draft monograph is iterative and allows for consistency.   
  
Dr. Freedman inquired which of the drugs would be greater than 250,000 prescriptions prescribed.  
Interim Director Sheehan stated Sections I and II of the draft monograph contain questions that when 
answered, may determine that the drug does not warrant further review at this time.   Dr. Freedman also 
noted that if we use the two criteria in the monograph to start the evaluation, then only a handful of drug 
products will be fully evaluated.  Associate Executive Director Dunn agreed and indicated that the 
application limits the universe of drugs that go through the entire monograph.   
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Mr. Feldman suggested adding overdose data to the preliminary review.  Dr. Freedman responded stating 
that the cause of death may not be due to that drug even if it is in his/her system.  Agree that it needs to 
be considered but not as a filtering question.  Mr. Feldman also asked questions about the process of 
reviewing the monograph.  Associate Executive Director Dunn noted that while the process hasn’t been 
defined, you will get packets in advance.  We summarize the information in the packets at the meetings 
and then discuss. 
 
Dr. Brandoff asked about how differences of mechanics of application will be addressed.  Associate 
Director Dunn indicated that for some, if they don’t have an ADF, then they will not go through the entire 
review process at this time. 
 
Dr. Carr noted that when designing a process like this, it is often helpful to bring in other end 
users/stakeholders.  Would that be possible as we want to make sure we aren’t leaving anything behind.  
Interim Director Sheehan asked the Commission to consider what this type of process may look like.  We 
will take it into consideration so please send me your thoughts. 
 
Dr. Doyle-Petrongolo asked if the monograph was just for the Commission or is a completed monograph 
meant to be for prescribers?  Interim Director Sheehan stated that it is just for the Commission.  Dr. 
Doyle-Petrongolo asked if questions 1 and 2 on the monograph both need to be answered “yes” to go on 
for further evaluation.  Interim Director Sheehan stated that it was a decision point for the Commission.  It 
was meant to help us prioritize the work and review of drug products.   
 
Dr. Carr suggested adding an asterisk that implies that the monograph may change if other drugs come on 
the market.   
 
Associate Executive Director Dunn will refine the monograph and bring back to the next meeting.   
 
CLOSING REMARKS/ADJOURNMENT 
 
Interim Director Sheehan thanked the Committee members for attending today’s meeting. He stated we 
made a lot of progress today and will continue this work at our November 5
th
  meeting. He acknowledged 
that it is possible that he will not be in attendance at the November 5
th
 meeting.  If so, Lindsey Tucker, 
Associate Commissioner at DPH, will chair the meeting.  I look forward to seeing you at the meeting on 
November 19th.  He added that Suzanne Cray will also be leaving for maternity leave in the upcoming 
weeks.  Once Suzanne transitions out, Lauren Nelson, the Policy Director at the Bureau of Health Care 
Safety and Quality, will serve in this capacity.  He stated, you will hear from Lauren regarding all meeting 
logistics and she will serve as a point of contact.   
 
Interim Director Sheehan asked for a motion to adjourn.  Dr. Carr motioned to adjourn, and Dr. Jeffrey 
seconded the motion. All members voted to adjourn. The meeting was adjourned at 11:52 AM.  
 
  
LIST OF DOCUMENTS PRESENTED TO THE DRUG FORMULARY COMMISSION FOR THIS MEETING: 
1. Docket of the meeting. 
2. Copies of the October 1, 2015 draft minutes. 
3. October 15, 2015 Meeting Presentation 
4. October 15, 2015 Draft Monograph 
 
 
